|G - Genito Urinary System and Sex Hormones|
|G03 - Sex Hormones and Modulators Of The Genital System|
Other hormones, see H - Systemic hormonal preparations, excl. sex hormones and insulins.
Sex hormones used only in the treatment of cancer (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents.
The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability. The DDDs of depot preparations are calculated as the dose divided by the dosing interval.
|G03C - Estrogens|
This group comprises estrogens and combinations, except combinations with
- androgens, see G03E
- progestogens, see G03F
- antiandrogens, see G03HB
Hormonal contraceptives, see G03A.
Estrogens used only in neoplastic diseases, see L - Antineoplastic and immunomodulating agents.
The DDDs are based on systemic use in postmenopausal estrogen substitution therapy and in the treatment of premenstrual ailments. However, for some preparations for vaginal administration the DDDs are based on local treatment.
The DDDs for transdermal preparations are based on the amount of active ingredient delivered per 24 hours and the number of days each patch is used.
|G03CA - Natural and Semisynthetic Estrogens, plain|
This group comprises preparations, which contain one or more natural or semisynthetic estrogen. Estradiol/polyestradiol are classified at the same 5th level. The same applies to estriol/polyestriol. Combinations of estradiol and estriol are classified in G03CA53.
Combinations with other drugs, see G03CC.
Estropipate is classified in G03CA07 - estrone.
The DDD for nasal administration of estradiol is based on daily treatment.
|G03CA03 - Estradiol|
| || || |
| || || |
| || || |
|0.3 mg||P||depot long duration|
|1 mg||P||depot short duration|
|5 mg||R|| |
|2 mg||O|| |
|0.3 mg||N|| |
|25 mcg||V|| |